Skip to main content
. 2023 May 12;13(11):1326–1345. doi: 10.1016/j.jpha.2023.05.002

Fig. 4.

Fig. 4

Fe-dihydromyricetin (DMY) nano-coordinated polymer particles (NCPs) reduce high glucose concentration-induced endothelial cell dysfunction and oxidative stress in vitro. (A) Expression of DNA polymerase delta interacting protein 2 (Poldip2), recombinant nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4), vascular cell adhesion molecule-1 (VCAM-1), hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF) in different groups of human umbilical vein endothelial cells (HUVEC) by Western blot (WB) experiments. (B−F) Quantification of Poldip2 (B), Nox4 (C), VCAM-1 (D), HIF-1α (E), and VEGF (F) expression in HUVEC from different groups of WB experiments in Fig. 4A. (G−K) Expression of Poldip2 (G), Nox4 (H), VCAM-1 (I), HIF-1α (J), and VEGF (K) in different groups of HUVEC was detected by enzyme-linked immunosorbent assay (ELISA). One-way analysis of variance (ANOVA) data represent the mean ± standard error of mean. ∗ represented the significant difference between the administered (intervention) group and the diabetic retinopathy (DR) control (DC) group, and # represented the significant difference between the normal control (NC) group and the DC group. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗/####P < 0.0001, compared with DC group using one-way ANOVA; ns: not significant. DC + Fe-DMY: DC with Fe-DMY NCPs treatment group (200 μg/mL); Fe-DMY NCPs concentrations in the different groups were: DC + Fe-DMY1, 200 μg/mL; DC + Fe-DMY2, 100 μg/mL; DC + Fe-DMY3, 50 μg/mL; and DC + Fe-DMY4, 10 μg/mL.